Comprehensive von Willebrand Factor Functional Activity Study
The comprehensive von Willebrand factor functional activity study assesses the function of a key blood clotting protein that ensures primary thrombus formation.
Von Willebrand factor participates in platelet attachment to the damaged vascular wall and their aggregation, as well as in stabilizing factor VIII.
Test composition (comprehensive assessment):
• Ristocetin cofactor activity index (vWF:RCo)
• Collagen-binding activity (vWF:CBA)
• Von Willebrand factor concentration (vWF:Ag)
Mechanism of abnormalities: decrease — hereditary defects (von Willebrand disease types 1, 2, and 3), acquired vWF defects, liver diseases, immune degradation, or increased factor consumption.
Biomaterial: Venous blood (plasma)
• Submit blood fasting
• Avoid alcohol for 24 hours
• Avoid physical exertion and stress 30 minutes before the test
Medications:
• If taking anticoagulants, antiplatelet agents, hormonal medications, or potent drugs, inform the doctor before the test.
Prescribed for:
• Suspected von Willebrand disease or other hereditary platelet disorders
• Tendency to frequent or spontaneous bleeding, nosebleeds, gum bleeding
• Monitoring therapy for detected vWF disorders
• Before surgical procedures or after surgery
Recommended for:
• Patients with frequent or unusual bleeding
• People with hereditary predisposition to von Willebrand disease
• Patients before surgery or after injuries
Reference values depend on the laboratory method and are indicated on the result form.
Decreased functional activity indicates functional vWF deficiency. Abnormalities require comprehensive assessment by a physician together with the clinical picture.
If abnormalities are detected: hematologist, general practitioner, cardiologist.
